DRADS Capital
VC Fund
Boston, United States
DRADS Capital is a Boston-based venture fund investing in life sciences, biotechnology, and A.I. companies focused on extending the boundaries of biomedical sciences. Our unique approach merges breakthrough science and technology from top academic laboratories and hospitals with strong leadership teams that are transforming how we treat and improveneurological health. Our portfolio of companies are unlocking human potential in treating neurodegenerative disease, improving mind-body wellness, and quantifying brain health.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries DRADS Capital invests in
Stages DRADS Capital invests in
Countries DRADS Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series C
- $26M–$78M
Investment Focus
Industry
- Health Care 6 (46%)
- Biotechnology 6 (46%)
- Medical 4 (31%)
- Biopharma 2 (15%)
- Neuroscience 2 (15%)
Stage
- Seed 3 (23%)
- Series C 3 (23%)
- Venture - Series Unknown 3 (23%)
- Series B 1 (8%)
- Series D 1 (8%)
Country
- United States 8 (62%)
- Chile 1 (8%)
- South Korea 1 (8%)
- United Arab Emirates 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
A. Nagarajan Pillay
Founding Managing Director
|
Founding Managing Director | Total investments: 0 | Find email | |
Kieran Nair
Partner
|
Partner | Total investments: 0 | Find email | |
James Hyun
Partner
|
Partner | Total investments: 0 | Find email | |
Negin Kalkan
Legal Partner
|
Legal Partner | Total investments: 0 | Find email | |
Rudolph Tanzi
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alsym™ Energy has developed an innovative low-cost, high-performance rechargeable energy storage technology that’s free of lithium and cobalt, and ideal for applications such as stationary storage, maritime shipping, and electric vehicles.By using readily available, inherently non-toxic and non-flammable energy storage materials, Alsym is workingto deliver wide-duration storage with performance comparable to lithium ion at a much lower cost, speeding the pace of decarbonization for people around the world. | $78M / Series C / Feb 22, 2024 | ||
| QuanticAsset develops AI-driven asset management and investment products for high-net-worth family offices and institutional investors. | Seed / Jan 01, 2024 | ||
| Driven by millennials, the plant-based foods market is already US$10Bn in size today. And it is projected to be US$25Bn by 2026. Visionaries like Bill Gates, Richard Branson & Leonardo Dicaprio have all invested big. In our pilot market, Chile, Jeff Bezos invested US$30Mn in the Not Co. But, the existing alternatives still use syntheticadditives, highly processed ingredients, and plastic packaging. And, their R&D costs millions of dollars and many years!That is why, at The Live Green Co, we use technology to make plant-based foods tastier, healthier & more sustainable. Our Recommendation Software (Charaka) blends our Ancestral Indian Science of Plant Nutrition and modern Tech, profiles the synthetic, processed & animal additives in our daily food, and recommends 100% natural plant-based Product Formulations... at just a fraction of the R&D cost & time! And, our Proprietary Production Process uses Natural Processing, Frugal Engineering & Circular Economy principles to cut down pollution, and usage of energy, land & water by more than 50%.It is no more about a few people following a sustainable lifestyle perfectly. It is about millions doing it, even if imperfectly. | $2M / Corporate Round / Jul 05, 2023 | ||
| Angiowave Provides shockwave therapy services intended to offer safe, comfortable treatment for men to optimize sexual performance. | Seed / Jan 01, 2023 | ||
| Driven by millennials, the plant-based foods market is already US$10Bn in size today. And it is projected to be US$25Bn by 2026. Visionaries like Bill Gates, Richard Branson & Leonardo Dicaprio have all invested big. In our pilot market, Chile, Jeff Bezos invested US$30Mn in the Not Co. But, the existing alternatives still use syntheticadditives, highly processed ingredients, and plastic packaging. And, their R&D costs millions of dollars and many years!That is why, at The Live Green Co, we use technology to make plant-based foods tastier, healthier & more sustainable. Our Recommendation Software (Charaka) blends our Ancestral Indian Science of Plant Nutrition and modern Tech, profiles the synthetic, processed & animal additives in our daily food, and recommends 100% natural plant-based Product Formulations... at just a fraction of the R&D cost & time! And, our Proprietary Production Process uses Natural Processing, Frugal Engineering & Circular Economy principles to cut down pollution, and usage of energy, land & water by more than 50%.It is no more about a few people following a sustainable lifestyle perfectly. It is about millions doing it, even if imperfectly. | $8M / Seed / Jan 05, 2022 | ||
| Zammo.ai, powered by Microsoft Azure, is the all-in-one conversational AI solution. Zammo eliminates complexity and enables organizations to rapidly launch powerful generative AI bots across voice, chat, and social channels—with just one click. Seamlessly integrating over 30 Azure services, including Azure OpenAI, Zammo enables organizations todeliver ChatGPT-like experiences using only their data—boosting engagement and user satisfaction. Built-in tools, live agent handoff, and effortless integration with existing systems streamlines setup and minimizes the need for custom development. Hosted securely on the customer’s Azure environment, Zammo ensures data remains private and compliant. Designed with accessibility at its core, Zammo helps organizations create inclusive, multilingual experiences that meet users where they are. Whether serving customers, students, or employees, Zammo makes it easy to get fast, reliable answers—anytime, anywhere. Future-proof and maintenance-free, Zammo automatically updates with the latest Azure capabilities, so your solution stays current without added effort. From first launch to ongoing optimization with real-time analytics and available analytics API, Zammo makes delivering smart, accessible, and engaging AI interactions effortless. | Venture - Series Unknown / Jan 01, 2022 | ||
| Hyperfine makes MRI accessible to every patient regardless of income or resources. | $90M / Series D / Feb 10, 2021 | ||
| MarvelBiome is a biopharmaceutical company with a vision of harnessing the power of microbes for treating various human diseases. It focuses on isolating, identifying, and characterizing microbial populations for novel therapeutic applications. | $5.4M / Venture - Series Unknown / Nov 17, 2020 | ||
| ROKIT Healthcare provides hardware, software, and application support. Their custom fabrication technologies deliver solutions to the design, creation, and applications of three-dimensional systems. They provide suffering patients and humans with a hyper-personalized medical organ regeneration solution. They apply artificial intelligence and 3dbioprinting technology to regenerate the skin and cartilage organs through surgery for patients. | Series C / Jul 09, 2020 | ||
| Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. The company features a drug designed to prevent nerve cell death and degeneration. Amylyx Pharmaceuticals was founded in 2014 and headquartered in Massachusetts, United States. | $30M / Series B / Jul 01, 2020 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does DRADS Capital invest in?
DRADS Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series C stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DRADS Capital's check size?
DRADS Capital typically joins rounds of $26M–$78M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DRADS Capital participates in.
How do I contact DRADS Capital?
Public channels for DRADS Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DRADS Capital?
The team at DRADS Capital includes A. Nagarajan Pillay (Founding Managing Director), Kieran Nair (Partner) and James Hyun (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
